MC
NVO

Middleton & Co’s Novo Nordisk NVO Stock Holding History

Middleton & Co’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-40,110
Closed -$945K – 146
2018
Q3 		$945K Hold
40,110
– – 0.15% 102
2018
Q2 		$925K Sell
40,110
-240
-0.6% -$5.7K 0.16% 102
2018
Q1 		$994K Hold
40,350
– – 0.18% 97
2017
Q4 		$1.08M Sell
40,350
-5,000
-11% -$127K 0.18% 98
2017
Q3 		$1.09M Buy
+45,350
New +$1.02M 0.2% 101

Other funds holding NVO

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
State Farm Mutual Automobile Insurance
State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return

Middleton & Co's NVO Position: Q4 2018 in Review

Middleton & Co sold out of Novo Nordisk (NVO) in Q4 2018, closing a stake of 40,110 shares — an estimated $945K sold.

Middleton & Co first reported a position in NVO in Q3 2017 and held it in 5 quarters. The position peaked at $1.09M in Q3 2017. 550 funds tracked by Wall St. Rank hold NVO as of Q4 2018.

  • Middleton & Co reported no remaining Novo Nordisk position as of Q4 2018 after selling out during the quarter.
  • Middleton & Co sold 40,110 Novo Nordisk shares in Q4 2018, an estimated $945K.
  • Middleton & Co first reported a position in Novo Nordisk in Q3 2017 and held it in 5 quarters.
  • Middleton & Co's Novo Nordisk position peaked at $1.09M in Q3 2017.
  • 550 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2018.

Based on Middleton & Co's 13F filing for Q4 2018, filed 1 Feb 2019.